RBC Capital Markets increased its price target for Eli Lilly to $1,600, up from $1,500.

Oct 30, 2026, 8:08 AM ETOpinionRead the original at marketscreener.com

Good for LLY

RBC raised its target after calling Eli Lilly's third-quarter results impressive, supporting a more positive view. It kept its Outperform rating, so the target changed but the rating did not.

LLY · Eli Lilly and Company

AI read · Good for LLY

The AI's read

The higher target and revised estimates show RBC expects stronger future performance. The rating did not change, but RBC's positive view remains in place. This is an analyst's estimate, not a promise from Eli Lilly.

Get alerts for LLY

Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LLY

Free on the App Store and Google Play, or on the web.